A Phase II randomized, double-blind, placebo-controlled, 26-week study to evaluate the efficacy, safety and tolerability of GLPG1205 in subjects with idiopathic pulmonary fibrosis
Phase of Trial: Phase II
Latest Information Update: 22 Nov 2019
Price : $35 *
At a glance
- Drugs GLPG 1205 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Acronyms PINTA
- Sponsors Galapagos NV
- 20 Nov 2019 Planned End Date changed from 16 May 2020 to 1 Aug 2020.
- 20 Nov 2019 Planned primary completion date changed from 25 Apr 2020 to 1 Jul 2020.
- 21 Feb 2019 According to a Galapagos NV media release, company plans to complete recruitment before year-end.